Stock Market Reviews

NVAX (Novavax, Inc.) News

Get the latest news, insights, and market updates on NVAX (Novavax, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Novavax (NVAX) Stock Trades Up, Here Is Why
  Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports revealed that its JN.1 Covid-19 vaccine became available at some GP clinics in Singapore.
  Jan 2, 2026 - $NVAX
• Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales
  Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close to analysts’ estimates. Its non-GAAP loss of $1.25 per share was 10.5% below analysts’ consensus estimates.
  Jan 1, 2026 - $NVAX
• Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
  Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
  Dec 30, 2025 - $NVAX
• Evaluating Novavax’s Current Valuation After Steep Five Year Share Price Collapse
  If you are wondering whether Novavax at around $6.66 is a hidden bargain or a classic value trap, you are not alone. That is exactly what we are going to unpack. Despite a bruising long-term track record, with the share price still down 23.4% over the last year and 94.9% over five years, the stock has tried to stabilize recently. It has gained 1.4% over 7 days and 2.9% over the last month, even though it remains down 22.3% year to date. Recent moves in Novavax have been shaped by shifting...
  Dec 21, 2025 - $NVAX
• Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
  Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Dec 19, 2025 - $NVAX
• Why I Wouldn't Touch Novavax With a 10-Foot Pole
  This stock could be a wealth destroyer in the next five years.
  Dec 11, 2025 - $NVAX
• Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
  Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
  Dec 8, 2025 - $NVAX
• Novavax, Inc. (NVAX): A Bull Case Theory
  We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.’s share was trading at $6.69 as of December 1st. NVAX’s trailing P/E was 3.33 according to Yahoo Finance. Novavax stands out as one of the few independent vaccine developers with a validated, […]
  Dec 5, 2025 - $NVAX
• Novavax (NVAX): Exploring Valuation After Prolonged Share Price Weakness
  Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest analysis for Novavax. At a latest share price of $6.84, Novavax’s 30 day share price return of minus 13.53% and five year total shareholder return of minus 94.06% show momentum has clearly been fading, despite occasional short term rallies. If Novavax’s volatility has you rethinking your biotech...
  Dec 4, 2025 - $NVAX
• Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
  Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
  Dec 2, 2025 - $NVAX